PP
ADMS

PDT Partners’s Adamas Pharmaceuticals ADMS Stock Holding History

PDT Partners’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-37,880
Closed -$164K – 938
2020
Q4 		$164K Buy
37,880
+6,455
+21% +$27.6K 0.01% 627
2020
Q3 		$129K Buy
+31,425
New +$122K 0.01% 668
2020
Q2 		– Sell
-78,300
Closed -$226K – 880
2020
Q1 		$226K Sell
78,300
-14,804
-16% -$66.3K 0.02% 535
2019
Q4 		$353K Buy
93,104
+39,904
+75% +$191K 0.02% 501
2019
Q3 		$272K Sell
53,200
-25,000
-32% -$154K 0.02% 382
2019
Q2 		$485K Buy
+78,200
New +$450K 0.03% 308
2015
Q4 		– Sell
-17,300
Closed -$290K – 1071
2015
Q3 		$290K Buy
17,300
+4,100
+31% +$93.3K 0.01% 1059
2015
Q2 		$346K Buy
13,200
+100
+0.8% +$1.95K 0.01% 1093
2015
Q1 		$229K Buy
+13,100
New +$224K 0.01% 1232

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

PDT Partners's ADMS Position: Q1 2021 in Review

PDT Partners sold out of Adamas Pharmaceuticals (ADMS) in Q1 2021, closing a stake of 37,880 shares — an estimated $164K sold.

PDT Partners first reported a position in ADMS in Q1 2015 and held it in 9 quarters. The position peaked at $485K in Q2 2019. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2021.

  • PDT Partners reported no remaining Adamas Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • PDT Partners sold 37,880 Adamas Pharmaceuticals shares in Q1 2021, an estimated $164K.
  • PDT Partners first reported a position in Adamas Pharmaceuticals in Q1 2015 and held it in 9 quarters.
  • PDT Partners's Adamas Pharmaceuticals position peaked at $485K in Q2 2019.
  • 73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2021.

Based on PDT Partners's 13F filing for Q1 2021, filed 17 May 2021.